StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38−0.07 (-4.83%)

Close on Nov 17, 2026Market cap $192.56MP/E –Yield –

Inhibikase Therapeutics cash

Cash and short-term investments held at the end of each period.

Inhibikase Therapeutics's cash was $159.02M at Jun 30, 2026. For fiscal 2025 it was $178.76M, up 83.3% from the year before. The highest annual figure on record is $178.76M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$178.76M+83.3%
FY2024Dec 31, 2024$97.54M+636.1%
FY2023Dec 31, 2023$13.25M-42.5%
FY2022Dec 31, 2022$23.05M-43.4%
FY2021Dec 31, 2021$40.75M+192.0%
FY2020Dec 31, 2020$13.95M+75500.1%
FY2019Dec 31, 2019$18.46K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$159.02M+81.4%
Q1 FY2026Mar 31, 2026$170.37M+82.8%
Q4 FY2025Dec 31, 2025$178.76M+83.3%
Q3 FY2025Sep 30, 2025$77.32M+2283.8%
Q2 FY2025Jun 30, 2025$87.67M+1004.1%
Q1 FY2025Mar 31, 2025$93.18M+855.8%
Q4 FY2024Dec 31, 2024$97.54M+636.1%
Q3 FY2024Sep 30, 2024$3.24M-80.7%
Q2 FY2024Jun 30, 2024$7.94M-62.1%
Q1 FY2024Mar 31, 2024$9.75M-62.1%
Q4 FY2023Dec 31, 2023$13.25M-42.5%
Q3 FY2023Sep 30, 2023$16.83M-36.6%
Q2 FY2023Jun 30, 2023$20.94M-35.0%
Q1 FY2023Mar 31, 2023$25.72M-29.8%
Q4 FY2022Dec 31, 2022$23.05M-43.4%
Q3 FY2022Sep 30, 2022$26.53M-43.3%
Q2 FY2022Jun 30, 2022$32.21M+235.2%
Q1 FY2022Mar 31, 2022$36.61M+162.4%
Q4 FY2021Dec 31, 2021$40.75M+251941.9%
Q2 FY2021Jun 30, 2021$46.84M+601525.6%
Q1 FY2021Mar 31, 2021$9.61M+73004.8%
Q4 FY2020Dec 31, 2020$13.95M+75500.1%
Q3 FY2020Sep 30, 2020$16.17K–
Q2 FY2020Jun 30, 2020$7.79K–
Q1 FY2020Mar 31, 2020$13.15K–
Q4 FY2019Dec 31, 2019$18.46K–

More Inhibikase Therapeutics figures

See a number that looks wrong?